Business Wire

Clientron Introduces Multi-Display Thin Client R800 and Q800 for VDI Solutions

20.6.2017 11:00 | Business Wire

Jaa

Clientron Corp., a global leading provider of thin clients, POS and embedded systems, has unveiled its innovative R800 and Q800 for streamlined thin client applications. The innovative R800 and Q800 both feature a durable fanless design and a reliable embedded platform in an eco-friendly form factor compliant with Energy Star 6.1. They are built to support virtual desktop solutions and cloud computing applications, meeting the demands of today's mainstream thin client market.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170620005028/en/

The Clientron R800 Thin Client based on Intel Quad Core processor supporting triple displays and 4K  ...

The Clientron R800 Thin Client based on Intel Quad Core processor supporting triple displays and 4K resolution for virtual desktop solutions. (Photo: Business Wire)

Reliable Embedded Platform and Innovate System Design

Both R800 and Q800 are based on Intel Braswell Refresh delivering 15 years of product life and outstanding performance on less power consumption. The R800 features a solid aluminum chassis and comes with Intel Celeron N3160 quad-core processor offering high flexibility and performance, while the Q800 features an ultra-compact design powered by Intel Celeron N3060 dual-core processor for entry-level to mainstream thin client applications. The innovative designs promise excellent durability with capacitive-touch power buttons for switching on/off the systems without a mechanical part.

High Flexibility and Enhanced Security Operation

To enable flexible expansion, the R800 offers 4K ultra-high-definition (UHD), supporting triple displays with two DisplayPorts and one HDMI port. In addition, the R800 features an innovative rotating ports-on-foot design with two built-in USB ports for expansion. Moreover, the R800 offers M.2 interfaces for optional WiFi modules, and it also supports optional PoE+ modules to provide up to 25W of power for the device. As a compact option, the Q800 offers 4K resolution dual displays with one DisplayPort and one HDMI port. The Q800 also supports the M.2 connector for system expansion. Both devices also support optional TPM 2.0 modules that are critical to providing a secure computing environment.

Best Virtual Desktop Solution for Mainstream Thin Clients

Built to serve as virtual desktop solutions, the R800 and Q800 support multiple protocols including Citrix HDX, Microsoft RDP and VMware Horizon View to enhance multimedia streaming performance and expand desktop experience to cloud computing. The R800 and Q800 can run Linux, WES7, WES8, Win10 IoT operating systems to satisfy diverse needs. The R800 is a high-performance and flexible thin client which can be adopted for banking, multimedia and medical care solutions. The Q800 is a compact thin client solution suitable for office, school, and call center operations.

The Clientron Thin Client R800 and Q800 are available now. For more product details, please contact Clientron's sales team or visit our website www.clientron.com

About Clientron

Clientron was founded in 1983. The company is dedicated to providing global intelligent solutions to our clients. With design, manufacturing and service abilities, Clientron offers high-quality and high-performance computing platforms including Thin Client, POS and Intelligent Systems. We are steadfast in our commitment to develop and provide even more advanced IoT client solutions and services for our partners and customers to build an intelligent e-World. Visit us at www.clientron.com.

Contact information

Clientron Corp.
Joan Chuang, 886-2-26987068
joan_chuang@clientron.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08Tiedote

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00Tiedote

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme